- Research article
- Open Access
- Open Peer Review
Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion
- Valentina Masola†1,
- Claudio Maran†1,
- Evelyne Tassone†1,
- Angelica Zin2,
- Angelo Rosolen2 and
- Maurizio Onisto1Email author
© Masola et al; licensee BioMed Central Ltd. 2009
- Received: 11 March 2009
- Accepted: 28 August 2009
- Published: 28 August 2009
Rhabdomyosarcoma (RMS) is a malignant soft tissue sarcoma of childhood including two major histological subtypes, alveolar (ARMS) and embryonal (ERMS) RMS. Like other human malignancies RMS possesses high metastatic potential, more pronounced in ARMS than in ERMS. This feature is influenced by several biological molecules, including soluble factors secreted by tumor cells, such as heparanase (HPSE). HPSE is an endo-β-D-glucuronidase that cleaves heparan sulphate proteoglycans.
We determined HPSE expression by Western blot analysis in ARMS and ERMS cells lines and activity in supernatants by an ELISA assay. Stable HPSE silencing has been performed by shRNA technique in RH30 and RD cell lines and their invasiveness has been evaluated by Matrigel-invasion assay. HPSE activity and mRNA expression have also been quantified in plasma and biopsies from RMS patients.
HPSE expression and activity have been detected in all RMS cell lines. Stable HPSE silencing by shRNA technique determined a significant knockdown of gene expression equal to 76% and 58% in RH30 and RD cell lines respectively and induced a less invasive behaviour compared to untreated cells. Finally, we observed that HPSE mRNA expression in biopsies was higher than in foetal skeletal muscle and that plasma from RMS patients displayed significantly more elevated HPSE levels than healthy subjects with a trend to higher levels in ARMS.
In conclusion, our data demonstrate for the first time HPSE expression and activity in RMS and highlight its involvement in tumor cell invasion as revealed by shRNA silencing. Moreover, HPSE expression in RMS patients is significantly higher with respect to healthy subjects. Further studies are warranted to assess possible relationships between HPSE and clinical behaviour in RMS.
- Heparan Sulphate
- Embryonal Rhabdomyosarcoma
- Wild Type Cell Line
- Heparanase Activity
- Foetal Skeletal Muscle
Rhabdomyosarcoma (RMS) is the most common soft-tissue cancer occurring in childhood. It originates from primitive mesenchymal cells committed to myogenic differentiation. RMS belongs to the broader category of small blue round cell tumors of childhood and histologically resembles normal foetal skeletal muscle . It can be classified into two main histological subtypes with distinct appearances and clinical behaviours. The rarer alveolar type (ARMS) arises mainly in the extremities and trunk. It is also associated with worse prognosis and higher disease stage at diagnosis. The unfavourable prognosis is related to the propensity for early and wide dissemination, often involving the lungs, bone marrow and bones and poor response to chemotherapy. In contrast, the embryonal rhabdomyosarcoma (ERMS) usually affects younger children, at more favourable sites, and shows a less aggressive clinical behaviour than ARMS [2, 3].
The frequent tumor dissemination and metastasis characteristics of ARMS, less common in ERMS, suggest a different expression of molecules involved in these events between the two subtypes. An important process in host tissue invasion is the extracellular matrix (ECM) degradation due to secreted and cell surface bound protease and glycosidase activities. These ECM-remodelling enzymes affect and modify cell and tissue functions . The ECM is composed of a complex network of macromolecules which fills the extracellular space in tissues and provides an essential physical barrier among cells, as well as a molecular scaffold for cell growth, migration, differentiation and survival. It also undergoes continuous remodelling during development and in a variety of pathological conditions such as cancer. While intensive research focused on enzymes capable of degrading protein components in the ECM has been established [5, 6], presently attention is directed towards enzymes (e.g., heparanase) cleaving glycosaminoglycan side chains. The heparan sulphate proteoglycans (HSPGs), the main polysaccharide component of the ECM, are ubiquitous macromolecules associated with the cell surface and the ECM of a wide range of cells in vertebrate and invertebrate tissues. Heparan sulphate (HS) plays a key role in the self-assembly and integrity of the ECM. In fact, HS chains can bind large number of proteins and several bioactive molecules like growth factors, chemokines, cytokines and enzymes to the cell surface and ECM, thereby regulating their availability and function in the control of some physiological processes, such as cell-cell and cell-ECM interactions . Malignant tumor growth, neo-vascularization and metastasis represent pathological invasive phenomena that involve the enzymatic degradation of the ECM. Heparanase (HPSE) is an endo-β-D-glucuronidase that cleaves HS side chains of HSPGs. Heparanase cleavage of HS in the ECM, particularly in epithelial and sub-endothelial basement membranes, is a critical step in cancer development and progression in correlation with metastatic potential, tumor vascularity and reduced survival of cancer patients . Its activity is regulated by gene expression and pro-enzyme activation. In fact heparanase is synthesized as a 65 kDa inactive precursor whose activation involves proteolytic cleavage, resulting in 8 and 50 kDa protein subunits that heterodimerize to form the active enzyme. Remarkably, the active form of heparanase is secreted in the extracellular environment [9, 10]. Recent studies have shown that this enzyme is upregulated in an increasing number of primary human tumors providing a strong clinical support for its pro-metastatic and pro-angiogenic features [11, 12], thus making it a promising target for the development of anti-cancer treatments [13, 14].
In contrast to frequent cancers occurring in adults, little information is available on RMS with regard to molecules involved in tumor invasion. We analyzed HPSE expression and activity in ARMS and ERMS cell lines and investigated the relationships of the different metastatic phenotype of ARMS and ERMS with expression and activity of heparanase.
Human alveolar rhabdomyosarcoma (ARMS) cell lines RH30, RH4, RH18, RH28 and human embryonal rhabdomyosarcoma (ERMS) cell lines RD, SMS-CTR, RH36, CCA were grown in RPMI (EuroClone, Pavia, Italy) supplemented with 10% foetal bovine serum (Biochrom AG, Berlin, Germany), 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 μg/ml). All cell lines were maintained at 37°C in a 5% CO2 water-saturated atmosphere.
Plasma and tumor RNA collection from RMS patients
A total of 3 ml of peripheral blood was obtained at the time of diagnosis in sodium citrate . All plasma samples were aliquoted, frozen at -80°C until analysis and thawed once.
The plasma study cohort consisted of 15 paediatric patients (5 with ARMS, 10 with ERMS) and 10 healthy subjects as control. In 12 out of 15 RMS cases (3 ARMS, 9 ERMS), tumor tissue was available for RNA purification. For RMS patients, the mean age was 6.3 years (range 1 – 15 yrs) with 8 girls and 7 boys at the time of diagnosis while, for healthy subjects, the mean age was 8.9 years (range 2 – 13 yrs) with 3 girls and 7 boys. Informed parental consent was obtained in each case.
RNA extraction and cDNA synthesis
Total RNA was extracted from cell monolayers using the "GenElute Mammalian Total RNA Miniprep" Kit (Sigma-Aldrich, Milan, Italy) including DNase treatment (DNASE70, Sigma), according to manufacturer's instructions.
Tumor RNA was isolated by using RNA-zol (Tel-Test, Friendswood, USA) following the manufacturer's instructions.
Yield and purity were checked by Nanodrop (EuroClone).
1 μg of total RNA from each sample was reverse transcribed into cDNA using 500 ng random primers and 200 U SuperScript II Reverse Transcriptase (Invitrogen, Milan, Italy).
Cloning of HPSE and GAPDH to obtain an internal standard
Sequences 5'→ 3'
d – ATTTGAATGGACGGACTGC
r – GTTTCTCCTAACCAGACCTTC
d – GCGGCGGTCACAGCTACTT
r – CACGCTCTTCAGACTTTGGTTCT
d – CCTGGAGACCTGAGAACCAATC
r – CCACCCGAGTGTAACCATAGC
d – TGCCATGCAGAAGTTTTACGG
r – TCCTTCGAACATTGGCCTTG
d – ACACCCACTCCTCCACCTTT
r – TCCACCACCCTGTTGCTGTA
Quantitative Real-time PCR
We performed a quantitative Real-time PCR assay based on the use of SYBR Green I (Applied Biosystems) as fluorescent intercalation dye into double-stranded DNA during the amplification cycles. The assays were performed in 96 multi-well PCR plates covered with optical tapes in the Applied Biosystems 7500 Real-time PCR System in a final volume of 25 μl, containing 10 ng of cDNA, 12.5 μl of Power Master Mix 2X (Applied Biosystems), 5 μmoles of either HPSE, Matrix Metalloproteinases (MMPs) or GAPDH forward and reverse primers, and water. The specific primer sequences are listed in Table 1.
The reaction was subjected to denaturation at 95°C for 10 minutes followed by 40 cycles of denaturation at 95°C for 30 seconds, annealing and elongation at 60°C for 1 minute.HPSE mRNA expression levels were evaluated by an absolute quantitative Real-time PCR in RMS cell lines and biopsies from RMS patients. Plasmids containing HPSE and GAPDH fragments were used as templates to obtain the standard curves. The relative HPSE mRNA expression levels were described as HPSE copy number/GAPDH copy number ratios. After the amplification, the software directly defined the standard curve of the experiment based on the Ct for each gene in analysis. In this way, a linear regression line was plotted and the resulting equation was used to calculate the copy number for the unknown samples .MMPs mRNA expression levels were evaluated by a relative quantitative Real-time PCR in RMS cell lines and normalized to GAPDH. The comparative Ct method (ΔΔCt) was used to quantify MMPs gene expression and the relative quantification (RQ) was calculated as 2-ΔΔCt. MMP2 expression level in RH30 wild type cell line was regarded as 100% and MMP2, MMP9 and MMP14 levels in the other samples were calculated relative to this value.
Sub-confluent cells were washed with PBS, lysed and scraped in lysis buffer [50 mM Tris-HCl (pH 5.0), 150 mM NaCl, 0.01% Triton X-100] with Protease Inhibitor Cocktail "Complete" (Roche, Milan, Italy). Cellular lysates were sonicated, centrifuged at 4°C for 30 minutes at 15,000 × g and finally quantified using Bio-Rad Protein Assay (Bio-Rad, Milan, Italy). Total proteins (50 μg) and platelet extract (5 μg) used as positive control were treated in reducing sample buffer [2% SDS, 80 mM Tris-HCl (pH 6.8), 10% glycerol, 0.005% bromophenol blue, 10% β-mercaptoethanol] and boiled for 10 minutes. Subsequently the samples were resolved in 9% SDS-PAGE and electro-transferred for 2.5 hours at 4°C to nitrocellulose membranes. Membranes were exposed to primary polyclonal antibody (sc-25825, Santa Cruz Biotechnolgy, Santa Cruz, CA). After three washes in TBST [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.05% Tween-20], the membranes were incubated with a secondary peroxidase-conjugated antibody (sc-2004, Santa Cruz Biotechnology). The signal was detected by "SuperSignals West Pico Chemiluminescent" substrate solution (Pierce, Rockford, IL), according to the manufacturer's instructions.
The quantitative detection of HPSE in RMS cell culture supernatants was performed with "Heparanase assay" Kit from AMS Biotechnology (Milton Abingdon, Oxon, UK) according to the manufacturer's instructions. Briefly, the ELISA plate was rehydratated by adding 100 μl of PBS and incubated at room temperature for 30 minutes. After removing PBS, 50 μl of the reaction buffer and 50 μl of samples were added in each well. 50 μl of reaction buffer and 50 μl of platelet protein extract diluted 1:100 in 1× Heparanase buffer were used as negative and positive controls respectively. The samples were serum-free conditioned media obtained from the different cell lines. The micro-well plate was then incubated 1 hour at 37°C and then each well was washed four times with PBT [PBS + 0.1% v/v Tween-20] and subsequently twice with PBS. To each well was added100 μl of the supplied Strep-HRP complex and incubated 1 hour at room temperature on a plate shaker. The micro-well plate was washed five times with PBS and subsequently 100 μl of peroxidase substrate were added at room temperature. The plate was gently shaken and the absorbance determined at 450 nm in an ELISA plate reader. Activity of each sample was calculated as described by the manufacturer and represented as ng of HS removed per minute.
Transfection of HPSE shRNA plasmid into RH30 and RD cell lines
shRNA 29 mer sequences
The HPSE gene-specific shRNA expression cassettes as well as the negative control shRNA pRS plasmid (TR20003) and the negative control shRNA pRS non-effective GFP plasmid (TR30003), were purchased from OriGene (Rockville, MD, USA). Transcribed shRNAs were reconstituted with 50 μl of RNase-Free water (Gibco, Invitrogen) to prepare a 100 ng/μl stock solution. RH30 and RD cell lines were seeded in 6-well plates at a density of 2.0 × 105 and 1.5 × 105 cells per well respectively. After 24 hours, cells at 70 – 80% confluence were transfected with 2 μg of each shRNA plasmid in serum-free medium using TransIT-LT1 transfection reagent (Mirus, Madison, WI) according to the manufacture's instruction. Control cells were treated with the same amount of TransIT-LT1 transfection reagent (Mock). 48 hours after transfection, RH30 and RD cells were placed for some weeks under selection with 0.5 and 1.0 μg/ml of puromycin (Sigma) respectively. From RH30 and RD cell lines, three different stable clones were selected for subsequent analysis.
The proliferation of RH30 and RD cell lines was evaluated by MTT assay. For both cell lines, wild type and silenced cells were tested as well as the relative negative controls. Cells in mid-log phase were seeded in 96-well culture plate and cultured for 24, 48 and 72 hours in their medium. Subsequently 10 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/ml in phosphate-buffered saline) was added to each well, cells were incubated for 4 h at 37°C and the precipitates were dissolved in 150 μl of dimethyl sulfoxide. The number of proliferating cells was evaluated by measuring optical density at 540 nm on a microtiter plate reader.
The invasive behaviour of ARMS RH30 and ERMS RD cell lines was assessed by using the Boyden-chamber assay according to the method of Albini et al. , with slight modifications. For both cell lines, wild type and silenced cells were tested as well as the relative negative controls. The filters used in the assay were "Isopore Membrane Filters" (Millipore, Milan, Italy) with pore size of 8.0 μm. Filters were coated with 50 μl of Matrigel solution (BD Biosciences, Milan, Italy), an artificial basement membrane that contains abundant HSPGs, previously prepared at a concentration of 0.225 μg/μl. Tumor cells (2.0 × 105 cells/ml) resuspended in 800 μl serum-free medium were layered on top of the polymerized gel in the upper compartment of the chamber while, in the lower compartment, conditioned serum-free medium from NIH3T3 cell line was used as chemo-attractant. After 5-hour incubation at 37°C, Matrigel was removed, the filters were washed in water, fixed in 100% ethanol for 5 minutes and stained with 1% toluidine blue/1% sodium tetraborate for 2 minutes. After staining, the filters were let to dry and photographed using Canon PowerShot G6 camera. Images were analyzed by ImageJ software http://rsb.info.nih.gov/ij/.
HPSE plasma assay
HPSE plasma activity was quantified according to the method of Xu et al. . This assay is based on the ability of HPSE to degrade heparan-sulphate proteoglycans present in the Matrigel. 25 μl of Matrigel was dissolved in ice-cold PBS at a concentration of 200 μg/ml and used to coat ELISA plates and left to dry at room temperature for 1.5 hour. Samples were diluted at 1:4 in HPSE buffer [0.1 M Sodium Acetate (pH 5.0), 0.1 mg/ml BSA, 0.01% Triton X-100, Protease Inhibitor Cocktail]. The plates were washed once with PBT [PBS + 0.05% v/v Tween-20] and then samples were added and incubated overnight at 37°C. The wells were washed with PBT and blocked with the appropriate buffer [PBT, 0.5% BSA, 1 mM EDTA] at room temperature for 2 hours. After PBT washing, primary monoclonal antibody anti-HS (clone HepSS-1, Seikagaku, Tokyo, Japan) diluted 1:500 was added and incubated in blocking buffer at room temperature for 1 hour. After PBT washing, goat anti-mouse IgM-HRP secondary antibody (sc-2973, Santa Cruz Biotechnology) diluted 1:1000 was added and incubated at room temperature for 1 hour. Then 50 μl of the ABTS [2,2-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid), Sigma] was added to each well. Finally, the reaction was blocked with 50 μl per well of 1% SDS and the OD405 absorbance was read in an ELISA plate reader.
HPSE activity in each plasma sample was calculated as the difference between the OD405 value with or without heparin (Sigma) at the final concentration of 50 μg/ml. This inhibitor was used to ensure the detection of the specific HPSE activity in plasma samples.
Differences in HPSE plasma levels and HPSE expression between RMS patients and controls were evaluated using the Mann-Whitney test with Bonferroni's Multiple Comparison correction. Differences between wild type and HPSE silenced cells were compared using the Students' t-test. A p value ≤ 0.05 was considered as the level of significance for all tests.
HPSE expression in RMS cell lines
HPSE activity in RMS cell lines
Stable HPSE silencing of RH30 and RD cell lines and invasion assay
MTT assay did not reveal any differences in cell proliferation between wild type and silenced cells (data not shown).
MMPs expression in RH30 and RD cell lines after stable HPSE silencing
In order to define whether MMPs expression changes after HPSE silencing, we evaluated MMP2, MMP9 and MMP14 expression in RH30 and RD wild type cells and in the corresponding silenced cells by a relative quantitative Real-time PCR.
On the whole MMP2 and MMP14 expression was higher in the alveolar RH30 cells respect to the embryonal RD.
HPSE expression and activity in RMS patients
HPSE expression was evaluated in 12 RMS biopsies by an absolute quantitative Real-time PCR, using normal foetal skeletal muscle cDNA as control.
HPSE activity in plasma samples collected at diagnosis from 15 RMS patients and from 10 healthy subjects was determined by an ELISA method. As shown in Figure 6B, we demonstrated that HPSE activity was significantly higher in plasma of RMS patients compared to healthy controls (P = 0.001). In addition, the five plasma samples obtained from ARMS patients showed higher activity levels of HPSE than ERMS, although the difference did not reach statistical significance (data not shown).
RMS is classified into two major histological groups: alveolar and embryonal. The rarer ARMS is more aggressive and associated with a significantly worse outcome than ERMS . The more frequent tumor dissemination and metastatic characteristic of ARMS, compared to ERMS, suggest that different enzymatic activities may be involved in host tissue invasion . Whereas upregulation of heparanase is well documented in an increasing number of human solid tumors showing a correlation with their invasive potential , its role has not been elucidated in RMS thus far.
Therefore, in the present study, we investigated HPSE expression and activity in RMS cell lines in order to establish whether any correlation between HPSE levels and histotype exists.
HPSE protein may be present both in the active/inactive form. Only the active one (50 kDa) is responsible for HS degradation in the ECM . Since HPSE mRNA expression results similar in all RMS cell lines analyzed, we performed a Western blot analysis to discriminate between the two isoforms.
All RMS cell lines showed the expression of HPSE protein. All ERMS cell lines along with RH18 and RH28 showed a similar and moderate expression of active HPSE isoforms and high levels of inactive HPSE isoforms. On the other hand, RH30 and RH4 cell lines were characterized by high levels of active HPSE and moderate expression of the inactive one. It was interesting that the total amount of HPSE protein, the active plus the inactive isoforms, was comparable in all RMS cell lines.
Furthermore, we evaluated HPSE activity by an ELISA assay on serum-free conditioned media from RMS cell lines. This assay confirmed a heterogeneous HPSE activity among RMS cell lines without a clear-cut difference between ARMS and ERMS cell lines.
The difference between active and inactive heparanase isoforms in RMS cell lines lysates and the discrepancy between the cytoplasmic amount of the enzyme and its activity in conditioned media could be explained in light of HPSE complex protein activation and secretion. In fact, heparanase is synthesized as a 65 kDa inactive precursor, shuttled to the Golgi apparatus and then secreted via vesicles. Once secreted, heparanase interacts with HSPGs forming a complex which is endocytosed. Conversion of endosome in lysosome results in HPSE cleavage, yielding 8 and 50 kDa protein subunit that heteodimerize to form the active enzyme [22, 23]. Moreover, heparanase active heterodimer can get secreted in response to local or systemic cues .
In order to determine the HPSE role in the ECM degradation associated with the different invasive potential in alveolar and embryonal histotypes, we stably silenced one cell line from each histotype by shRNA technique. Based on the ELISA assay results, we selected ARMS RH30 and ERMS RD cell lines characterized by the highest HPSE activity in the conditioned media. After puromycin selection, clones appearing to be silenced more than 50% were chosen from both cell lines. Using a Matrigel-invasion assay, we demonstrated that HPSE silencing significantly reduced the invasive potential of RH30 and RD cell lines compared with the untreated cells. Although previous experiments demonstrated a relevant role of other ECM degrading enzymes , HPSE silencing emphasizes the importance of this enzyme both in alveolar and embryonal RMS invasiveness. Because Zcharia E. et al. have recently demonstrated in a knock-out mouse model that absence of HPSE expression was associated with an increased expression of MMPs , we determined the effects of HPSE silencing in RH30 and RD cell lines by analyzing the expression of MMP2, MMP9 and MMP14. In our cellular model we did not observe the same phenomenon since HPSE silencing did not result in significant differences of MMPs expression in silenced vs. wild type cells. In addition, after HPSE silencing, no change in cell proliferation was observed by MTT analysis.
It has recently been observed that elevated HPSE levels in patients' blood correlates with a poor prognosis . For this reason we analyzed by an ELISA assay HPSE activity in plasma samples from RMS patients and healthy subjects. RMS patients showed a statistically significant higher heparanase activity with respect to healthy individuals. Coherently, a significantly higher expression of HPSE transcripts was assessed in biopsies from RMS patients compared to foetal skeletal muscle tissue used as normal counterpart of the tumor.
Although high HPSE plasma levels have been previously reported in other paediatric malignancies , this is the first demonstration of a significantly high HPSE expression in RMS patients. Additionally, although it should be interpreted with caution due to the limited number of patients, there is some suggestion of higher HPSE plasma levels in ARMS compared with ERMS patients. Further clinical and histo-pathological analyses on larger cohorts of RMS patients are necessary to establish whether HPSE may be considered as a novel marker able to distinguish the more aggressive ARMS from ERMS. Since a single functional heparanase has been identified so far , the relevant effect of the specific gene knockdown described here should encourage the development of novel heparanase-targeting therapeutic approaches aimed at inhibiting RMS invasive potential.
In conclusion, we detected for the first time HPSE expression and activity in RMS and showed its implication in tumor cell invasiveness in vitro. We also demonstrated a significantly high HPSE expression in RMS patients with a trend to higher levels in ARMS.
This work was supported by the Ministero dell'Università e della Ricerca (MIUR) (Cofin 2006). Further support was obtained from former 60% contribution (Padova University grant), from Associazione Italiana per la Ricerca sul Cancro (AIRC) and from Fondazione Città della Speranza. The authors wish to thank Dr. Chiara Romualdi and Dr. Gloria Tridello for statistical analysis.
- Merlino G, Helman LJ: Rhabdomyosarcoma – working out the pathways. Oncogene. 1999, 18 (38): 5340-5348. 10.1038/sj.onc.1203038.View ArticlePubMedGoogle Scholar
- Breitfeld PP, Meyer WH: Rhabdomyosarcoma: new windows of opportunity. Oncologist. 2005, 10 (7): 518-527. 10.1634/theoncologist.10-7-518.View ArticlePubMedGoogle Scholar
- Wijnaendts LC, Linden van der JC, van Unnik AJ, Delemarre JF, Voute PA, Meijer CJ: Histopathological classification of childhood rhabdomyosarcomas: relationship with clinical parameters and prognosis. Hum Pathol. 1994, 25 (9): 900-907. 10.1016/0046-8177(94)90009-4.View ArticlePubMedGoogle Scholar
- Duffy MJ, McGowan PM, Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol. 2008, 214 (3): 283-293. 10.1002/path.2282.View ArticlePubMedGoogle Scholar
- Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature. 2001, 411 (6835): 375-379. 10.1038/35077241.View ArticlePubMedGoogle Scholar
- Stetler-Stevenson WG, Yu AE: Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 2001, 11 (2): 143-152. 10.1006/scbi.2000.0365.View ArticlePubMedGoogle Scholar
- Yung S, Chan TM: Glycosaminoglycans and proteoglycans: overlooked entities?. Perit Dial Int. 2007, 27 (Suppl 2): S104-9.PubMedGoogle Scholar
- Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A: Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem. 2005, 96 (5): 897-905. 10.1002/jcb.20602.View ArticlePubMedGoogle Scholar
- Parish CR, Freeman C, Hulett MD: Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta. 2001, 1471 (3): M99-108.PubMedGoogle Scholar
- Vlodavsky I, Goldshmidt O, Zcharia E, Metzger S, Chajek-Shaul T, Atzmon R, Guatta-Rangini Z, Friedmann Y: Molecular properties and involvement of heparanase in cancer progression and normal development. Biochimie. 2001, 83 (8): 831-839. 10.1016/S0300-9084(01)01318-9.View ArticlePubMedGoogle Scholar
- Vlodavsky I, Ilan N, Naggi A, Casu B: Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des. 2007, 13 (20): 2057-2073. 10.2174/138161207781039742.View ArticlePubMedGoogle Scholar
- Ilan N, Elkin M, Vlodavsky I: Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006, 38 (12): 2018-2039. 10.1016/j.biocel.2006.06.004.View ArticlePubMedGoogle Scholar
- Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z: Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem. 2006, 13 (18): 2101-2111. 10.2174/092986706777935230.View ArticlePubMedGoogle Scholar
- Simizu S, Ishida K, Osada H: Heparanase as a molecular target of cancer chemotherapy. Cancer Sci. 2004, 95 (7): 553-558. 10.1111/j.1349-7006.2004.tb02485.x.View ArticlePubMedGoogle Scholar
- Shafat I, Barak AB, Postovsky S, Elhasid R, Ilan N, Vlodavsky I, Arush MW: Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia. 2007, 9 (11): 909-916. 10.1593/neo.07673.View ArticlePubMedPubMed CentralGoogle Scholar
- Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonak J, Lind K, Sindelka R, Sjoback R, Sjogreen B, Strombom L, Stahlberg A, Zoric N: The real-time polymerase chain reaction. Mol Aspects Med. 2006, 27 (2–3): 95-125. 10.1016/j.mam.2005.12.007.View ArticlePubMedGoogle Scholar
- Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987, 47 (12): 3239-3245.PubMedGoogle Scholar
- Xu X, Quiros RM, Maxhimer JB, Jiang P, Marcinek R, Ain KB, Platt JL, Shen J, Gattuso P, Prinz RA: Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res. 2003, 9 (16 Pt 1): 5968-5979.PubMedGoogle Scholar
- Onisto M, Slongo ML, Gregnanin L, Gastaldi T, Carli M, Rosolen A: Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol. 2005, 27 (3): 791-798.PubMedGoogle Scholar
- McKenzie EA: Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol. 2007, 151 (1): 1-14. 10.1038/sj.bjp.0707182.View ArticlePubMedPubMed CentralGoogle Scholar
- Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, Gready JE, Parish CR: Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry. 2000, 39 (51): 15659-15667. 10.1021/bi002080p.View ArticlePubMedGoogle Scholar
- Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky I, Ilan N: Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci. 2004, 117 (Pt 11): 2249-2258. 10.1242/jcs.01068.View ArticlePubMedGoogle Scholar
- Nadav L, Eldor A, Yacoby-Zeevi O, Zamir E, Pecker I, Ilan N, Geiger B, Vlodavsky I, Katz BZ: Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J Cell Sci. 2002, 115 (Pt 10): 2179-2187.PubMedGoogle Scholar
- Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, Peretz T, Vlodavsky I, Li JP: Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS ONE. 2009, 4 (4): e5181-10.1371/journal.pone.0005181.View ArticlePubMedPubMed CentralGoogle Scholar
- Quiros RM, Rao G, Plate J, Harris JE, Brunn GJ, Platt JL, Gattuso P, Prinz RA, Xu X: Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival. Cancer. 2006, 106 (3): 532-540. 10.1002/cncr.21648.View ArticlePubMedGoogle Scholar
- Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I: Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med. 1999, 5 (7): 793-802. 10.1038/10518.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/9/304/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.